<?xml version='1.0' encoding='utf-8'?>
<document id="30739368"><sentence text="Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries."><entity charOffset="39-49" id="DDI-PubMed.30739368.s1.e0" text="ombitasvir" /><entity charOffset="50-62" id="DDI-PubMed.30739368.s1.e1" text="paritaprevir" /><pair ddi="false" e1="DDI-PubMed.30739368.s1.e0" e2="DDI-PubMed.30739368.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30739368.s1.e0" e2="DDI-PubMed.30739368.s1.e1" /></sentence><sentence text="Ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin (OBV/PTV/r ± DSV ± RBV) regimens show high efficacy and good tolerability in clinical trials for chronic hepatitis C virus (HCV) genotypes (GT) 1 or 4"><entity charOffset="0-10" id="DDI-PubMed.30739368.s2.e0" text="Ombitasvir" /><entity charOffset="11-23" id="DDI-PubMed.30739368.s2.e1" text="paritaprevir" /><entity charOffset="24-33" id="DDI-PubMed.30739368.s2.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.30739368.s2.e0" e2="DDI-PubMed.30739368.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30739368.s2.e0" e2="DDI-PubMed.30739368.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30739368.s2.e0" e2="DDI-PubMed.30739368.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30739368.s2.e1" e2="DDI-PubMed.30739368.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30739368.s2.e1" e2="DDI-PubMed.30739368.s2.e2" /></sentence><sentence text=" To evaluate whether these results translate to clinical practice, data were pooled from observational studies across 13 countries" /><sentence text=" Treatment-naïve or -experienced patients, with or without cirrhosis, received OBV/PTV/r ± DSV ± RBV according to approved local labels and clinical practice" /><sentence text=" Sustained virologic response at post-treatment Week 12 (SVR12), adverse events (AEs) and comedication management were assessed for patients initiating treatment before 1 June 2017" /><sentence text=" The safety population included 3850 patients who received ≥1 dose of study drug" /><sentence text=" The core population (N = 3808) further excluded patients with unknown GT or cirrhosis status, or who received off-label treatment" /><sentence text=" Patients had HCV GT1a (n = 732; 19%), GT1b (n = 2619; 69%) or GT4 (n = 457; 12%)" /><sentence text=" In 3546 patients with sufficient follow-up data at post-treatment Week 12, the SVR12 rate was 96% (n/N = 3401/3546 [95% CI 95" /><sentence text="2-96" /><sentence text="5])" /><sentence text=" In patients with or without cirrhosis, SVR12 was comparable (96%)" /><sentence text=" In patients with HCV GT1a, GT1b or GT4, SVR12 rates were 93%, 97% and 94%" /><sentence text=" In GT1b-infected patients with planned treatment for 8 weeks, SVR12 was 96%" /><sentence text=" In patients with ≥1 comorbidity (67%), SVR12 was 95%" /><sentence text=" 58% of patients received ≥1 comedication, and there was minimal impact on SVR12 rates using comedications for peptic ulcers and gastro-esophageal reflux disease, statins, antipsychotics or antiepileptics" /><sentence text=" Most comedications were maintained during treatment although 58% of patients changed their statin medication" /><sentence text=" AEs and serious AEs occurred in 26% and 3% of patients" /><sentence text=" Post-baseline Grade 3-4 laboratory abnormalities were rare (&lt;3%), and discontinuation rates were low (&lt;4%)" /><sentence text=" Real-world evidence confirms the effectiveness of OBV/PTV/r ± DSV ± RBV in patients with HCV GT1 or GT4, regardless of common comorbidities or comedications, and is consistent with clinical trial results" /><sentence text=" Adverse safety outcomes may be limited by underreporting in the real-world setting" /><sentence text="" /></document>